Neetu Godhwani, MD
Allergy & Immunology · Danbury, CTNPI 1235530155
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 374 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 21.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,963, 2.2 times the $905 reported in 2019.
Across 374 payments — averaging $20.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- AstraZeneca$1K
- Sanofi$901
- Takeda Pharmaceuticals U.S.A., Inc.$541
- Novartis$532
- Regeneron Healthcare Solutions, Inc.$417
- plus $3K from 22 others
What the payments were for
- Food & beverage$7,703100%
- Education$370%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 113 | $1,639 |
| AstraZeneca | 48 | $1,104 |
| Sanofi | 34 | $901 |
| Takeda Pharmaceuticals U.S.A., Inc. | 25 | $541 |
| Novartis | 25 | $532 |
| Regeneron Healthcare Solutions, Inc. | 19 | $417 |
| Pfizer | 19 | $383 |
| Genentech USA, Inc. | 15 | $366 |
| Amgen | 13 | $343 |
| Biocryst US Sales Co., LLC | 3 | $302 |
| CSL Behring | 10 | $299 |
| Boehringer Ingelheim | 10 | $174 |
| Optinose US, Inc. | 8 | $145 |
| Kaleo, Inc. | 8 | $141 |
| Alk-abello, Inc | 5 | $81 |
| Octapharma USA, Inc. | 3 | $53 |
| Teva Pharmaceuticals USA, Inc. | 3 | $50 |
| Pharming Healthcare, Inc. | 2 | $45 |
| Grifols USA, LLC | 2 | $38 |
| Blueprint Medicines Corporation | 1 | $26 |
| AbbVie | 1 | $26 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $24 |
| Ionis Pharmaceuticals, Inc. | 1 | $24 |
| Aimmune Therapeutics, Inc. | 1 | $21 |
| Shire North American Group Inc | 1 | $20 |
| Incyte Corporation | 1 | $19 |
| Cycle Pharmaceuticals Inc | 1 | $14 |
| Hikma Pharmaceuticals USA | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,740 in reported general payments places this provider in the 75th percentile of 54 allergy & immunology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CuvitruImmun Glob G(Igg)/Gly/Iga Ov50 | 16 | $67,239 |
| TezspireTezepelumab-Ekko | 13 | $58,541 |
| Breo ElliptaFluticasone/Vilanterol | 60 | $34,932 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $17,227 |
| SymbicortBudesonide/Formoterol Fumarate | 46 | $12,294 |
| DuleraMometasone/Formoterol | 24 | $8,847 |
| Epinephrine | 63 | $7,481 |
| Arnuity ElliptaFluticasone Furoate | 19 | $5,528 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 33 | $4,716 |
| RyaltrisOlopatadine Hcl/Mometasone | 19 | $4,682 |
| Fluticasone Propionate HfaFluticasone Propionate | 14 | $3,424 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 38 | $3,312 |
| BreynaBudesonide/Formoterol Fumarate | 16 | $2,874 |
| Azelastine Hcl | 91 | $2,615 |
| Wixela InhubFluticasone Propion/Salmeterol | 23 | $2,380 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTezspire, Symbicort | $1,104 | $70,83559 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Cuvitru | $541 | $67,23916 claims |
| GSKBreo Ellipta, Trelegy Ellipta, Arnuity Ellipta | $1,639 | $57,688100 claims |
| Hikma Pharmaceuticals USAEpinephrine, Ryaltris | $12 | $12,16282 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 54 allergy & immunology providers in Connecticut.
Other allergy & immunology in Danbury
- Richard LeeDanbury$3K
- Purvi ShahDanbury$3K
- Yogen DaveDanbury$610
- Jonathan BellDanbury$279
- Gavin SchwarzWest Hartford$262K
- Christina PriceNew Haven$96K
- Florence HsuNorth Haven$84K
- Jason LeeWest Hartford$30K
- Birur ChandraEast Haven$15K
- Michael KingTrumbull$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.